| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lion’s Mane mushroom (Hericium erinaceus; “HE”; culinary + medicinal mushroom). Key bioactives include erinacines (notably erinacine A; typically mycelium-derived) and hericenones (often fruiting-body-associated), plus polysaccharides (β-glucans). Primary mechanisms (conceptual rank): Bioavailability / PK relevance: activity depends strongly on extract type (mycelium vs fruiting body; erinacine-standardized vs not). Some erinacines are reported to be BBB-permeable in the literature; human PK is not well-characterized for most commercial products. In-vitro vs oral exposure: many anti-cancer / signaling findings use extract concentrations likely above achievable systemic levels from typical supplements (qualifier: high concentration only unless otherwise demonstrated in vivo). Clinical evidence status: small human trials/pilot RCTs for cognition/early AD/MCI and healthy adults (signals but limited); cancer evidence remains largely preclinical/adjunct-hypothesis. Lion’s Mane Mushroom (Hericium erinaceus) is renowned for its potential health benefits, particularly in areas like neuroprotection, cognitive function, and immune support.-Most commonly cited mechanisms of Lion’s Mane is its ability to stimulate the synthesis of Nerve Growth Factor (NGF) -Specific compounds such as hericenones and erinacines present in the mushroom are thought to be responsible for this effect. -May inhibit NF-κB Pathway -May lower the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6) -Neutralize free radicals, reducing oxidative stress -Lion’s Mane influences gut health and, in turn, the gut-brain axis -Anti-inflammatory responses, antioxidant protection -Mushrooms, including Lion’s Mane (Hericium erinaceus), contain ergosterol—a precursor to vitamin D. When exposed to ultraviolet (UV) light (such as sunlight), ergosterol is converted to vitamin D₂ (ergocalciferol). Lion’s Mane (Hericium erinaceus) — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr AD relevance: Lion’s Mane (Hericium erinaceus; especially erinacine-A–enriched mycelium preparations) is primarily studied as a neurotrophic + neuroprotective dietary intervention with small human trials/pilot RCTs in early AD/MCI and related cognitive outcomes. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: effects depend on standardized preparations (erinacine A content; dosing regimen). Evidence base includes a ~49-week pilot double-blind placebo-controlled study of erinacine-A–enriched mycelium; overall evidence remains limited by sample sizes and product variability. Clinical evidence status: small human trials/pilot RCTs (signals but not definitive; adjunct/early evidence). Lion’s Mane (Hericium erinaceus) — AD/Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells. The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment. Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS). – In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer. • Expression Patterns in Tumors: – Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment. – Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation. |
| 3814- | mushLions, | Lion's Mane (Hericium erinaceus) Exerts Anxiolytic Effects in the rTg4510 Tau Mouse Model |
| - | in-vitro, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:325 Target#:563 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid